Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment

Stock Information for Charlottes Web Holdings Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Charlottes Web Holdings Inc

Charlotte's Web Reports Shareholder Meeting Voting Results
AJNA BioSciences and Charlotte's Web to Spotlight Cannabis' Pharmaceutical Future at Benzinga Cannabis Capital Conference Featuring DeFloria
Charlotte's Web(TM) Unveiling Brightside(TM) Precision-Formulated Approach to Hemp-Derived THC at Benzinga Conference
Charlotte's Web Reports Year-Over-Year Growth For Q1 2025
Charlotte's Web Reports 2024 Fourth Quarter and Year-End Financial Results
Charlotte's Web 2024 Fourth Quarter Earnings Call and Webcast Notice
DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)
Charlotte's Web Provides Update on DeFloria's Phase 1 Results Targeting Autism Spectrum Disorder

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.